It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
A main feature of neurodegenerative diseases is the loss of neurons. One of the most prevalent neurodegenerative illnesses is Parkinson disease (PD). Although several medications are already approved to treat neurodegenerative disorders, most of them only address associated symptoms. The main aim of the current study was to examine the neuroprotective efficacy and underlying mechanism of Lobophytum sp. crude extract in a rotenone-induced rat model of neurodegeneration mimicking PD in humans. The influence of the treatment on antioxidant, inflammatory, and apoptotic markers was assessed in addition to the investigation of TH (tyrosine hydroxylase) immunochemistry, histopathological changes, and α-synuclein. Metabolomic profiling of Lobophytum sp. crude extract was done by using High-Resolution Liquid Chromatography coupled with Mass Spectrometry (HR-LC–ESI–MS), which revealed the presence of 20 compounds (1–20) belonging to several classes of secondary metabolites including diterpenoids, sesquiterpenoids, steroids, and steroid glycosides. From our experimental results, we report that Lobophytum sp. extract conferred neuroprotection against rotenone-induced PD by inhibiting ROS formation, apoptosis, and inflammatory mediators including IL-6, IL-1β, and TNF-α, NF-кB, and subsequent neurodegeneration as evidenced by decreased α-synuclein deposition and enhanced tyrosine hydroxylase immunoreactivity. Moreover, a computational network pharmacology study was performed for the dereplicated compounds from Lobophytum sp. using PubChem, SwissTarget Prediction, STRING, DisGeNET, and ShinyGO databases. Among the studied genes, CYP19A1 was the top gene related to Parkinson’s disease. Dendrinolide compounds annotated a high number of parkinsonism genes. The vascular endothelial growth factor (VEGF) pathway was the top signaling pathway related to the studied genes. Therefore, we speculate that Lobophytum sp. extract, owing to its pleiotropic mechanisms, could be further developed as a possible therapeutic drug for treating Parkinson's disease.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 King Abdulaziz University, Department of Pharmacy Practice, Faculty of Pharmacy, Jeddah, Saudi Arabia (GRID:grid.412125.1) (ISNI:0000 0001 0619 1117)
2 Deraya University, Department of Biochemistry and Molecular Biology, Faculty of Pharmacy, New Minia City, Egypt (GRID:grid.412125.1); Deraya University, Deraya Center for Scientific Research, New Minia City, Egypt (GRID:grid.412125.1)
3 Minia University, Drug Information Center, Faculty of Pharmacy, Minia, Egypt (GRID:grid.411806.a) (ISNI:0000 0000 8999 4945)
4 Deraya University, Department of Medical Science, Histology and Cell Biology, Faculty of Pharmacy, New Minia City, Egypt (GRID:grid.411806.a)
5 University of Tabuk, Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, Tabuk, Saudi Arabia (GRID:grid.440760.1) (ISNI:0000 0004 0419 5685)
6 Fujairah Research Centre, Fujairah, United Arab Emirates (GRID:grid.440760.1); El Saleheya El Gadida University, Department of Pharmacognosy, Faculty of Pharmacy, El Saleheya El Gadida, Egypt (GRID:grid.440760.1)
7 University of Würzburg, Institute of Organic Chemistry, Würzburg, Germany (GRID:grid.8379.5) (ISNI:0000 0001 1958 8658)
8 Deraya University, Deraya Center for Scientific Research, New Minia City, Egypt (GRID:grid.8379.5); Minia University, Department of Pharmacognosy, Faculty of Pharmacy, Minia, Egypt (GRID:grid.411806.a) (ISNI:0000 0000 8999 4945)
9 Al-Azhar University, Department of Pharmacognosy and Medicinal Plants, Faculty of Pharmacy (Girls), Cairo, Egypt (GRID:grid.411303.4) (ISNI:0000 0001 2155 6022)